Advancing the Development of Autologous & Allogeneic CAR-T Therapies for Haematological & Solid Tumours
- Discussing the challenges in evaluating CAR-T cell therapies preclinically and the rationale to select relevant preclinical models
- Presenting lessons learned to tackle antigen expression and ensure the representation of the patient tumour microenvironment
- Leveraging model data to predict efficacy and safety of CAR-T therapies to ensure translation to the clinic